Information on Lonza Operations Related to the Current Coronavirus Outbreak (Updated)
UPDATED 5 March 2020 – Lonza’s manufacturing facilities in China are all operational. Lonza has not experienced any significant disruption arising from issues relating to COVID-19 (Coronavirus) and we do not currently anticipate any impact on our continuing ability to meet customer demand.
UPDATED 5 February 2020 – Lonza has received approval from the authorities to resume production at the majority of our facilities in China. We reiterate that we do not anticipate any disruption to our customers.
Basel, Switzerland, 3 February 2020 – Since the outbreak of the Coronavirus, we have continued to diligently monitor the development of the outbreak and taken measures to safeguard our employees and supply chain at our sites located in the People’s Republic of China.
Our production sites in China include:
Nanjing, Jiangsu (LSI formulation and Pyromellitic Dianhydride Production)
Nansha, Guangdong (LPBN small molecule API, LSI Niacin production)
Suzhou, Jiangsu (LPBN capsules and LSI Microbial Control Solutions)
Guangzhou, Guangdong (LPBN mammalian manufacturing)
The Guangzhou site is currently under construction and is not yet operational. Lonza does not have a production facility in the Hubei Province, the location in which the Coronavirus was originally detected.
Most of Lonza’s facilities have taken the decision to extend the Chinese New Year holiday period into the week of 3 February, pending further guidance from local authorities, and are currently not operating. Lonza has continuous operations at some facilities that were not shut down over the holiday period and these processes continue. Any customers who may be affected by the extended closure are being informed on a case by case basis, but presently there is limited disruption. As the outbreak progresses, we are assessing the impact of potential delays to raw material delivery and finished goods delivery across our global facilities.
As a responsible employer, we have taken measures to protect our employees and any third parties visiting our sites in China. Measures include temperature checks and the provision of disinfectants and personal protection devices (such as face masks). We have also implemented restrictions on business travel to, from and within China. For any employees travelling from China to another country, we have implemented a 14-day stay-at-home policy upon arrival, to prevent any potential spread of the virus. Our colleagues are well-informed of the risks with regular global updates and are cooperating fully with preventative measures.